A Form 4 filed on September 1, 2026 reports that Steven Pieper, Chief Financial Officer of Xeris Biopharma Holdings, Inc., sold 5,000 shares of common stock on September 1, 2026 pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Steven Pieper, identified in the filing as Chief Financial Officer of Xeris Biopharma Holdings, Inc.
  • Shares sold: 5,000 shares of common stock disposed of (transaction code S) on September 1, 2026
  • Sale price: $8.5 per share, as stated in the filing
  • Remaining ownership: 1,356,053 shares of common stock beneficially owned directly following the transaction
  • 10b5-1 plan: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025
  • Filing form: Filed by one reporting person; ownership is direct

Xeris Biopharma CFO Transaction Details and Plan Background

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Steven Pieper, the Chief Financial Officer of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), disposed of 5,000 shares of the company's common stock on September 1, 2026, at a price of $8.5 per share. The filing indicates the transaction was direct and carries transaction code S, denoting a sale.

The filing discloses that the sale was carried out under a Rule 10b5-1 trading plan that Pieper adopted on August 18, 2025. Rule 10b5-1 plans allow corporate insiders to establish pre-scheduled trading arrangements at a time when they are not in possession of material non-public information. The filing's cover box confirms the transaction is being reported as made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Following the reported transaction, the filing states that Pieper directly holds 1,356,053 shares of Xeris Biopharma Holdings common stock. No derivative securities transactions were reported in Table II of the filing. The form was signed by Beth Hecht as Attorney-in-Fact on September 1, 2026.

What Was Disclosed

The filing reports the sale of 5,000 shares of Xeris Biopharma Holdings common stock by CFO Steven Pieper at $8.5 per share on September 1, 2026, under a pre-adopted Rule 10b5-1 plan, leaving him with direct beneficial ownership of 1,356,053 shares.